Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Aligos Therapeutics, Inc. (ALGS) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Aligos Therapeutics, Inc. (ALGS), most recent 12 months reported: revenue $3.74M, net loss $75.96M, free cash flow -$94.52M. Latest balance sheet on file: liquid cash $30.38M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Prime Medicine, Inc. · OCUGEN, INC. · CURIS, INC. · DYADIC INTERNATIONAL INC · Humacyte, Inc. · SCINAI IMMUNOTHERAPEUTICS LTD. · INHIBRX BIOSCIENCES, INC. · Pluri Inc.

Stock screener

Watchlist